Floatz logo

Carboplatin

Additional Indications Below for Module 4 and 5

AstraZenecaSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Additional Indications Below for Module 4 and 5 cohort.

Asset / SponsorPhaseRating
T-Dxd
AstraZeneca
Phase 1/2CCC
Camizestrant
AstraZeneca
Phase 1/2CCC
Datopotamab Deruxtecan
AstraZeneca
Phase 1/2CCC
azd5305
AstraZeneca
Phase 1/2CCC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →